Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

Fig. 4

Kaplan-Meier curves for all patients treated with gemcitabine + MK-0646 compared with gemcitabine + MK-0646 + erlotinib during phase I and II (randomization and expansion) cohorts. a Kaplan-Meier progression-free survival curves for patients treated with gemcitabine + MK-0646 compared with gemcitabine + MK-0646 + erlotinib. b Kaplan-Meier overall survival curves for patients treated with gemcitabine + MK-0646 compared with gemcitabine + MK-0646 + erlotinib

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us